1188 related articles for article (PubMed ID: 23439252)
41. High False Positivity in Positron Emission Tomography is a Potential Diagnostic Pitfall in Patients with Suspected Adrenal Metastasis.
Lang BH; Cowling BJ; Li JY; Wong KP; Wan KY
World J Surg; 2015 Aug; 39(8):1902-8. PubMed ID: 25809060
[TBL] [Abstract][Full Text] [Related]
42. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
43. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
44. 68Ga-DOTANOC PET/CT in Adrenal Schwannoma.
Aggarwal P; Singh H; Kumar R; Nada R; Bora GS; Walia R
Clin Nucl Med; 2023 Jan; 48(1):e22-e23. PubMed ID: 36469076
[TBL] [Abstract][Full Text] [Related]
45. Comparison of diagnostic efficacy of
Zhang B; He Q; Long Y; Zhang Y; Wang X; Chen Z; Liu J; Zhang X
Front Endocrinol (Lausanne); 2022; 13():962800. PubMed ID: 36213295
[TBL] [Abstract][Full Text] [Related]
46. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
Lu Y; Xie D; Huang W; Gong H; Yu J
Neoplasma; 2010; 57(2):129-34. PubMed ID: 20099976
[TBL] [Abstract][Full Text] [Related]
47. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
48. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
50. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
[TBL] [Abstract][Full Text] [Related]
51. 18F-FDG PET/CT in the evaluation of adrenal masses.
Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.
Erasmus JJ; Patz EF; McAdams HP; Murray JG; Herndon J; Coleman RE; Goodman PC
AJR Am J Roentgenol; 1997 May; 168(5):1357-60. PubMed ID: 9129444
[TBL] [Abstract][Full Text] [Related]
53. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
Nunes ML; Rault A; Teynie J; Valli N; Guyot M; Gaye D; Belleannee G; Tabarin A
World J Surg; 2010 Jul; 34(7):1506-10. PubMed ID: 20396886
[TBL] [Abstract][Full Text] [Related]
55. Risk stratification of adrenal masses by [
Salgues B; Guerin C; Amodru V; Pattou F; Brunaud L; Lifante JC; Mirallié E; Sahakian N; Castinetti F; Loundou A; Baumstarck K; Sebag F; Taïeb D
Clin Endocrinol (Oxf); 2021 Feb; 94(2):133-140. PubMed ID: 32978795
[TBL] [Abstract][Full Text] [Related]
56. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.
Ansquer C; Scigliano S; Mirallié E; Taïeb D; Brunaud L; Sebag F; Leux C; Drui D; Dupas B; Renaudin K; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1669-78. PubMed ID: 20490488
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
58. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
[TBL] [Abstract][Full Text] [Related]
59. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic accuracy of
Kim SJ; Lee SW; Pak K; Kim IJ; Kim K
Br J Radiol; 2018 Jun; 91(1086):20170520. PubMed ID: 29327944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]